NeoTIL-ACT

N/A

Report date: 2026/04/17 10:36:37

Base Information

Drug NameNeoTIL-ACT

Drug Alias Nameautologous tumor-infiltrating lymphocyte therapy (Centre Hospitalier Universitaire Vaudois)

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Tumor Infiltrating Lymphocytes

Mechanisms of ActionUpdating

TargetsUpdating

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritorySwitzerland

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesCentre Hospitalier Universitaire Vaudois

China Registration ClassN/A

Develop Information

Active CompaniesCentre Hospitalier Universitaire Vaudois

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsN/A

Other Information

ATC CodeN/A